

PROGRAM SITE:	REVIEW DATE:
REVIEWER(S):	

CORE SERVICES

Outpatient/Ambulatory Health Services Tool - 2018 (OLD)

*Action Item for 2019
Review of Tool*

CORE SERVICES

Outpatient/Ambulatory Health Services Tool - 2019 (NEW)

SECTION 1: CHART REVIEW

SECTION 1: CHART REVIEW

Review for newly diagnosed HIV patients and new patients to the practice (within the last year) (Y = present; N = not present; NA = not applicable)

Review for newly diagnosed HIV patients and new patients to the practice (within the last year) (Y = present; N = not present; NA = not applicable)

INITIAL MEDICAL EVALUATION/ASSESSMENT

INITIAL MEDICAL EVALUATION/ASSESSMENT

NEWLY DIAGNOSED/NEW TO CARE	1	Linkage to Care Percentage of patients who attended a routine HIV medical care visit within 3 months of HIV diagnosis. <i>(HRSA HAB measure)</i>	Archive
	2	Comprehensive HIV related History Percentage of new patients with a documented comprehensive HIV related history that is inclusive of all components listed in the OAHs Standard as referenced in the HHS guidelines.	Maintain
	3	Physical Exam: Percentage of new patients with a documented annual physical examination including complete review of systems.	Maintain (add include oral cavity)
	4	Initial Oral Cavity Exam documented	Archive (part of physical exam)
	5	Oral Health Examination Documentation that an oral examination by a dentist was completed at least once during the measurement year (based on self report or other documentation). <i>(HRSA HAB Measure)</i>	Maintain

NEWLY DIAGNOSED/NEW TO CARE	1	Comprehensive HIV related History: Percentage of new patients with a documented comprehensive HIV related history that is inclusive of all components listed in the OAHs Standard as referenced in the HHS guidelines.
	2	Physical Exam: Percentage of new patients with a documented annual physical examination to include examination of the oral cavity.
	3	Oral Health Examination: Documentation that an oral examination by a dentist was completed at least once during the measurement year (based on self report or other documentation). <i>(HRSA HAB Measure)</i>

INITIAL LABORATORY TESTS, AS CLINICALLY INDICATED BY LICENSED PROVIDER

INITIAL LABORATORY TESTS, AS CLINICALLY INDICATED BY LICENSED PROVIDER

NEWLY DIAGNOSED/NEW TO CARE	6	HIV Antibody, if not documented previously	Archive
	7	CD4 Count and/or CD4 Percentage	Maintain (add timeframe)
	8	Quantitative Plasma HIV RNA (HIV Viral Load): Percentage of patients with documented HIV-RNA viral load. <i>(HRSA HAB Measure)</i>	Maintain
	9	Drug Resistance Testing (genotype, phenotype) - recommended at time of initial care: Percentage of new patients with documented drug resistance testing, as applicable.	Maintain
	10	Co-receptor Tropism Test (if considering use of CCR5 co-receptor antagonist or for patients who exhibit virologic failure on a CCR5 antagonist)	Archive
	11	HLA-B*5701 testing (only before initiating abacavir-containing regimen per guidelines)	Archive
	12	Complete Blood Count (CBC) with Differential and Platelets	Maintain
	13	Chemistry Profile: Electrolytes, Creatinine, Blood Urea Nitrogen (BUN)	Maintain
	14	Liver Transaminases, Bilirubin (Total and Direct)	Archive
	15	Urinalysis with Urine Protein and Creatinine	Maintain (remove protein and creatinine)
	16	Quantitative HCV RNA viral load testing (for Hepatitis C positive patients who are candidates for treatment)	Maintain (follow after HCV screening)
	17	Hepatitis A total antibody, Hepatitis B surface antigen, core Ab, and surface antibody & Hepatitis C antibody screens at initial intake (providers should screen all HIV-infected patients for anti-HCV antibodies at baseline)	Maintain
	18	Hepatitis B: Percentage of new patients, regardless of age, for whom Hepatitis B screening was performed at least once since the diagnosis of HIV/AIDS or for whom there is documented infection or immunity. <i>(HRSA HAB Measure)</i>	Maintain
	19	Hepatitis C: Percentage of new patients for whom Hepatitis C (HCV) screening was performed at least once since the diagnosis of HIV. <i>(HRSA HAB Measure)</i>	Maintain
	20	Lipid Profile (Total Cholesterol, LDL, HDL, Triglycerides); Fasting	Maintain
	21	Glucose (preferably fasting) or hemoglobin A1C	Archive (remove/component of metabolic panel)
	22	Pregnancy Test (for female clients of childbearing potential)	Archive
	23	Serum VDRL or RPR or treponemal antibody (Syphilis Screening): Percentage of new adult patients with a diagnosis of HIV who had a test for syphilis performed within the measurement year. <i>(HRSA HAB Measure)</i>	Maintain

NEWLY DIAGNOSED/NEW TO CARE	4	CD4 Count and/or CD4 Percentage: Percentage of patients with a documented CD4 during the measurement year.
	5	Quantitative Plasma HIV RNA (HIV Viral Load): Percentage of patients with documented HIV-RNA viral load at least once during the measurement year.
	6	Drug Resistance Testing (Genotype/Phenotype): Percentage of new patients with documented drug resistance testing.
	7	Complete Blood Count (CBC) with Differential and Platelets: Percentage of patients with a documented CBC with Differential and Platelets during the measurement year.
	8	Comprehensive Metabolic Panel (CMP): Percentage of patients with a documented Comprehensive Metabolic Panel (CMP) during the measurement year.
	9	Lipid Panel: Percentage of patients, regardless of age, with a diagnosis of HIV who were prescribed HIV antiretroviral therapy and who had a fasting lipid panel during the measurement year. <i>(HRSA HAB Measure)</i>
	10	Urinalysis (UA): Percentage of patients with a documented Urinalysis during the measurement year.
	11	Hepatitis A: Percentage of patients for whom a Hepatitis A Total Antibody screening was performed at least once since the diagnosis of HIV or for whom there is documented infection or immunity.
	12	Hepatitis B: Percentage of new patients, regardless of age, for whom Hepatitis B screening (Hepatitis B surface antigen and surface antibody) was performed at least once since the diagnosis of HIV/AIDS or for whom there is documented infection or immunity. <i>(HRSA HAB Measure)</i>
	13	Hepatitis C: Percentage of new patients for whom Hepatitis C (HCV) screening was performed at least once since the diagnosis of HIV. <i>(HRSA HAB Measure)</i>
	14	Quantitative HCV RNA Viral Load: Percentage of patients that are Hepatitis C positive and who are candidates for Hepatitis C treatment with a Hepatitis C RNA Viral Load test during the measurement year.
	15	Serum VDRL or RPR or treponemal antibody (Syphilis Screening): Percentage of new adult patients with a diagnosis of HIV who had a test for syphilis performed within the measurement year. <i>(HRSA HAB Measure)</i>
	16	Gonorrhea (GC) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for gonorrhea within the measurement year. <i>(HRSA HAB Measure)</i>
	17	Chlamydia (CT) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for chlamydia within the measurement year. <i>(HRSA HAB Measure)</i>

24	Gonorrhea (GC) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for gonorrhea within the measurement year. <i>(HRS A HAB Measure)</i>	Maintain
25	Chlamydia (CT) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for chlamydia within the measurement year. <i>(HRS A HAB Measure)</i>	Maintain
26	Toxoplasma gondii IgG	Archive
27	Trichomoniasis Testing	Archive
28	Percentage of new patients with documented initial laboratory tests completed according to the OAHS Standard and HHS Treatment Guidelines	Archive

OTHER DIAGNOSTIC TESTING

29	Percentage of new patients with documented chest x-ray completed if pulmonary symptoms were present or LTBI test was positive.	Maintain
----	--	----------

INITIAL SCREENINGS/ASSESSMENTS

30	Percentage of new patients with documented initial medical screenings and assessments as indicated in the OAHS Standard and in accordance with HHS guidelines	Archive
31	Child Abuse Assessment: Percentage of new patients, if applicable, with completed child abuse assessment (completed if patient aged 14 years and younger).	Maintain
32	Cervical Cancer Screen: Percentage of new female patients with a diagnosis of HIV who were screened for cervical cancer in the last three years. <i>(HRS A HAB Measure)</i>	Maintain
33	Cervical Cancer Screen for HIV-infected Women Aged <30 years: If known to be HIV-infected or newly diagnosed with HIV, and sexually active, screen within 1 year of onset of sexual activity regardless of mode of HIV infection	Archive (consolidate ages)
34	Cervical Cancer Screen Women Aged 21-29: Initial Pap test following initial diagnosis then every 12 months. If results of 3 consecutive Pap tests are normal, follow up Pap tests can be performed every 3 years.	Archive (consolidate ages)
35	Cervical Cancer Screen Women Aged >30 Years: Pap test should be done at baseline and every 12 months. If results of 3 consecutive Pap test are normal, follow-up Pap tests can be performed every 3 years.	Archive (consolidate ages)
36	Pap Test and HPV Co-Testing: Pap test and HPV co-testing should be done at baseline.	Archive
37	Mental Health Assessment: Percentage of new patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen. <i>(HRS A HAB Measure)</i>	Maintain
38	Substance Use and Abuse Screening: Percentage of new patients with diagnosis of HIV who have been screened for substance use (alcohol & drugs) in the measurement year. <i>(HRS A HAB Measure)</i>	Maintain
39	Psychosocial Assessment: Percentage of new patients with documented initial psychosocial assessment to include domestic violence and housing status.	Maintain
40	Tuberculosis (TB) Screening: Percentage of new patients aged 3 months and older with a diagnosis of HIV/AIDS, for whom there was documentation that a tuberculosis (TB) screening test was performed and results interpreted (for TB skin tests) at least once since the diagnosis of HIV infection. <i>(HRS A HAB Measure)</i>	Maintain
41	Tobacco Use Screening: Percentage of new patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user. <i>(HRS A HAB Measure)</i>	Maintain (separate screening and cessation counseling)

SECTION 2: Chart Review

****Review for all patients in care on (1) year or more with same medical provider****

42	Medical Evaluation/Assessment: Percentage of existing patients (return to care and those in current medical care for more than one year) with a documented comprehensive assessment/evaluation completed by the MD, NP, CNS, or PA within 15 business days of initial contact with patient in accordance with professional and established HIV	Archive
43	Comprehensive HIV related History Percentage of existing patients with a documented comprehensive HIV related history that is inclusive of all components listed in the OAHS Standard as referenced in the HHS guidelines.	Maintain
44	Physical Exam Percentage of existing patients with a documented annual physical examination including complete review of systems conducted during the comprehensive medical history.	Maintain (add include oral cavity)
45	Oral Cavity Exam documented	Archive (part of physical exam)
46	Oral Health Examination Documentation that an oral examination by a dentist was completed at least once during the measurement year (based on self report or other documentation). <i>(HRS A HAB Measure)</i>	Maintain

INITIAL SCREENINGS/ASSESSMENTS

18	Child Abuse Assessment: Percentage of new patients, if applicable, with completed child abuse assessment (completed if patient aged 14 years and younger).	NEWLY DIAGNOSED/NEW TO CARE
19	Cervical Cancer Screen: Percentage of new female patients with a diagnosis of HIV who were screened for cervical cancer in the last three years. <i>(HRS A HAB Measure)</i>	
20	Mental Health Assessment: Percentage of new patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen. <i>(HRS A HAB Measure)</i>	
21	Substance Use and Abuse Screening: Percentage of new patients with diagnosis of HIV who have been screened for substance use (alcohol & drugs) in the measurement year. <i>(HRS A HAB Measure)</i>	
22	Psychosocial Assessment: Percentage of new patients with documented initial psychosocial assessment to include domestic violence and housing status.	
23	Tuberculosis (TB) Screening: Percentage of new patients aged 3 months and older with a diagnosis of HIV/AIDS, for whom there was documentation that a tuberculosis (TB) screening test was performed and results interpreted (for TB skin tests) at least once since the diagnosis of HIV infection. <i>(HRS A HAB Measure)</i>	
24	Chest X-Ray: Percentage of new patients with documented chest x-ray completed if pulmonary symptoms were present or LTBI test was positive.	
25	Tobacco Use Screening: Percentage of new patients aged 18 years and older who were screened for tobacco use one or more times within 24 months. <i>(HRS A HAB Measure)</i>	

SECTION 2: Chart Review

****Review for all patients in care on (1) year or more with same medical provider****

26	Comprehensive HIV related History: Percentage of existing patients with a documented comprehensive HIV related history that is inclusive of all components listed in the OAHS Standard as referenced in the HHS guidelines.	EXISTING PATIENTS/ ONGOING MEDICAL CARE
27	Physical Exam: Percentage of existing patients with a documented annual physical examination to include examination of the oral cavity.	
28	Oral Health Examination: Documentation that an oral examination by a dentist was completed at least once during the measurement year (based on self report or other documentation). <i>(HRS A HAB Measure)</i>	

ONGOING MEDICAL CARE - LABORATORY TESTS, AS CLINICALLY INDICATED BY LICENSED PROVIDER				ONGOING MEDICAL CARE - LABORATORY TESTS, AS CLINICALLY INDICATED BY LICENSED PROVIDER			
EXISTING PATIENTS/ONGOING MEDICAL CARE	47	HIV Antibody, if not documented previously	Archive	ONGOING MEDICAL CARE	29	CD4 Count and/or CD4 Percentage: Percentage of patients with a documented CD4 during the measurement year.	
	48	CD4 Count and/or CD4 Percentage	Maintain		30	Quantitative Plasma HIV RNA (HIV Viral Load): Percentage of patients with documented HIV-RNA viral load at least once during the measurement year.	
	49	Quantitative Plasma HIV RNA (HIV Viral Load): Percentage of patients with documented HIV-RNA viral load. (HRSAB HAB Measure)	Maintain		31	Complete Blood Count (CBC) with Differential and Platelets: Percentage of patients with a documented CBC with Differential and Platelets during the measurement year.	
	50	Co-receptor Tropism Test (if considering use of CCR5 co-receptor antagonist or for patients who exhibit virologic failure on a CCR5 antagonist)	Archive		32	Comprehensive Metabolic Panel (CMP): Percentage of patients with a documented Comprehensive Metabolic Panel (CMP) during the measurement year.	
	51	HLA-B*5701 testing (only before initiating abacavir-containing regimen per guidelines)	Archive		33	Lipid Panel: Percentage of patients, regardless of age, with a diagnosis of HIV who were prescribed HIV antiretroviral therapy and who had a fasting lipid panel during the measurement year. (HRSAB HAB Measure)	
	52	Complete Blood Count (CBC) with Differential and Platelets	Maintain		34	Urinalysis (UA): Percentage of patients with a documented Urinalysis during the measurement year.	
	53	Chemistry Profile: Electrolytes, Creatinine, Blood Urea Nitrogen (BUN)	Maintain		35	Hepatitis A Total Antibody: Percentage of patients for whom a Hepatitis A Total Antibody screening was performed at least once since the diagnosis of HIV or for whom there is documented infection or immunity.	
	54	Liver Transaminases, Bilirubin (Total and Direct)	Archive		36	Hepatitis B Screen: Percentage of existing patients, regardless of age, for whom Hepatitis B screening was performed at least once since the diagnosis of HIV/AIDS or for whom there is documented infection or immunity. (HRSAB HAB Measure)	
	55	Urinalysis with Urine Protein and Creatinine	Maintain (remove protein and creatinine verbiage)		37	Hepatitis C Screen: Percentage of existing patients for whom Hepatitis C (HCV) screening was performed at least once since the diagnosis of HIV. (HRSAB HAB Measure)	
	56	Quantitative HCV RNA viral load testing (for Hepatitis C positive patients who are candidates for treatment)	Maintain		38	Quantitative HCV RNA Hep C Viral Load: Percentage of patients with a diagnosis of Hepatitis C patients who are candidates for Hepatitis C treatment with a Hepatitis C RNA Viral Load test during the measurement year.	
	57	Lipid Profile (Total Cholesterol, LDL, HDL, Triglycerides); Fasting	Maintain		39	Serum VDRL or RPR or treponemal antibody (Syphilis Screening): Percentage of adult patients with a diagnosis of HIV who had a test for syphilis performed within the measurement year. (HRSAB HAB Measure)	
	58	Glucose (preferably fasting) or hemoglobin A1C	Archive (already a component of CMP)		40	Gonorrhea (GC) Testing: Percentage of existing patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for gonorrhea within the measurement year. (HRSAB HAB Measure)	
	59	Pregnancy Test (for female clients of childbearing potential)	Archive		41	Chlamydia (CT) Testing: Percentage of existing patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for chlamydia within the measurement year. (HRSAB HAB Measure)	
	60	Serum VDRL or RPR or treponemal antibody (Syphilis Screening): Percentage of new adult patients with a diagnosis of HIV who had a test for syphilis performed within the measurement year. (HRSAB HAB Measure)	Maintain				
	61	Gonorrhea (GC) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for gonorrhea within the measurement year. (HRSAB HAB Measure)	Maintain				
	62	Chlamydia (CT) Testing: Percentage of new patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for chlamydia within the measurement year. (HRSAB HAB Measure)	Maintain				
	63	Toxoplasma gondii IgG	Archive				
	64	Trichomoniasis Testing	Archive				
OTHER DIAGNOSTIC TESTING							
	65	Percentage of existing patients with documented chest x-ray completed if pulmonary symptoms were present, after an initial positive Interferon Gamma Release Assay (IGRA), after initial positive TST, or annually if prior evidence of LTBI or pulmonary TB.	Maintain (move under TB)				
FOLLOW-UP VISITS							
	66	Percentage of existing patients with documented initial medical screenings and assessments as indicated in the OAHs Standard and in accordance with HHS guidelines.	Archive	FOLLOW UP VISITS	42	HIV Medical Visit Frequency: Percentage of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in each 6-month period of the 24-month measurement period with a minimum of 60 days between medical visits. (HRSAB HAB Measure)	
	67	HIV Medical Visit Frequency: Percentage of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in each 6-month period of the 24-month measurement period with a minimum of 60 days between medical visits. (HRSAB HAB Measure)	Maintain		43	Gap in Medical Visits: Percentage of patients, regardless of age, with a diagnosis of HIV who did not have a medical visit in the last 6 months of the measurement year. (HRSAB HAB Measure)	
	68	Gap in Medical Visits: Percentage of patients, regardless of age, with a diagnosis of HIV who did not have a medical visit in the last 6 months of the measurement year. (HRSAB HAB Measure)	Maintain		44	Viral Load Suppression: Percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year. (HRSAB HAB Measure)	
	69	Viral Load Suppression: Percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year. (HRSAB HAB Measure)	Maintain		45	Child Abuse Assessment: Percentage of existing patients, if applicable, with completed child abuse assessment (completed if patient aged 14 years and younger).	
	70	Cervical Cancer Screen: Percentage of new female patients with a diagnosis of HIV who were screened for cervical cancer in the last three years. (HRSAB HAB Measure)	Maintain		46	Cervical Cancer Screen: Percentage of existing female patients with a diagnosis of HIV who were screened for cervical cancer in the last three years. (HRSAB HAB Measure)	
	71	Cervical Cancer Screen for HIV-infected Women Aged <30 years: If known to be HIV-infected or newly diagnosed with HIV, and sexually active, screen within 1 year of onset of sexual activity regardless of mode of HIV infection	Archive (consolidate ages)		47	Mental Health Assessment: Percentage of existing patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen. (HRSAB HAB Measure)	
	72	Cervical Cancer Screen Women Aged 21-29: Initial Pap test following initial diagnosis then every 12 months. If results of 3 consecutive Pap tests are normal, follow up Pap tests can be performed every 3 years.	Archive (consolidate ages)		48	Substance Use and Abuse Screening: Percentage of existing patients with diagnosis of HIV who have been screened for substance use (alcohol & drugs) in the measurement year. (HRSAB HAB Measure)	
	73	Cervical Cancer Screen Women Aged >30 Years: Pap test should be done at baseline and every 12 months. If results of 3 consecutive Pap test are normal, follow-up Pap tests can be performed every 3 years.	Archive (consolidate ages)		49	Psychosocial Assessment: Percentage of existing patients with documented initial psychosocial assessment to include domestic violence and housing status.	

74	Pap Test and HPV Co-Testing: Pap test and HPV co-testing should be done at baseline.
75	Syphilis Screening: Percentage of existing adult patients with a diagnosis of HIV who had a test for syphilis performed within the measurement year. <i>(HRSAB HAB Measure)</i>
76	Serologic Test for Syphilis: Percentage of existing patients with documented serologic test for syphilis performed. <i>(HRSAB HAB Measure)</i>
77	Gonorrhea (GC) Testing: Percentage of existing patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for gonorrhea within the measurement year. <i>(HRSAB HAB Measure)</i>
78	Chlamydia (CT) Testing: Percentage of existing patients with a diagnosis of HIV at risk for sexually transmitted infections (STIs) who had a test for chlamydia within the measurement year. <i>(HRSAB HAB Measure)</i>
79	Mental Health Assessment: Percentage of existing patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen. <i>(HRSAB HAB Measure)</i>
80	Substance Use and Abuse Screening: Percentage of existing patients with diagnosis of HIV who have been screened for substance use (alcohol & drugs) in the measurement year. <i>(HRSAB HAB Measure)</i>
81	Psychosocial Assessment: Percentage of existing patients with documented initial psychosocial assessment to include domestic violence and housing status.
82	Tuberculosis (TB) Screening: Percentage of existing patients aged 3 months and older with a diagnosis of HIV/AIDS, for whom there was documentation that a tuberculosis (TB) screening test was performed and results interpreted (for TB skin tests) at least once since the diagnosis of HIV infection. <i>(HRSAB HAB Measure)</i>
83	Tobacco Use Screening: Percentage of existing patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user. <i>(HRSAB HAB Measure)</i>
84	Hepatitis B Screen: Percentage of existing patients, regardless of age, for whom Hepatitis B screening was performed at least once since the diagnosis of HIV/AIDS or for whom there is documented infection or immunity. <i>(HRSAB HAB Measure)</i>
85	Hepatitis C Screen: Percentage of existing patients for whom Hepatitis C (HCV) screening was performed at least once since the diagnosis of HIV. <i>(HRSAB HAB Measure)</i>
86	Lipid Panel: Percentage of patients, regardless of age, with a diagnosis of HIV who were prescribed HIV antiretroviral therapy and who had a fasting lipid panel during the measurement year. <i>(HRSAB HAB Measure)</i>

Archive
Duplicate/Remove
Duplicate/Remove
Duplicate/Remove
Duplicate/Remove
Maintain
Duplicate/Remove
Maintain
Duplicate/Remove

50	Tuberculosis (TB) Screening: Percentage of existing patients aged 3 months and older with a diagnosis of HIV/AIDS, for whom there was documentation that a tuberculosis (TB) screening test was performed and results interpreted (for TB skin tests) at least once since the diagnosis of HIV infection. <i>(HRSAB HAB Measure)</i>
51	Chest X-Ray: Percentage of existing patients with documented chest x-ray completed if pulmonary symptoms were present, after an initial positive Interferon Gamma Release Assay (IGRA), after initial positive TST, or annually if prior evidence of L/TBI or pulmonary TB.
52	Tobacco Use Screening: Percentage of existing patients aged 18 years and older who were screened for tobacco use one or more times within 24 months. <i>(HRSAB HAB Measure)</i>

SECTION 3: Chart Review

<i>IMMUNIZATIONS (Y = present; N = not present; N/A = not applicable)</i>	
87	Tetanus, Diphtheria, and Pertussis current within 10 years, Td booster doses every 10 years thereafter, or documentation of refusal.
88	Documentation that pediatric patients had at least one dose of Measles, Mumps, Rubella (MMR) vaccine administered between 12-24 months of age, or documentation of refusal. <i>(HRSAB HAB measure for pediatrics)</i>
89	Influenza vaccine given to patients aged 6 months or older between October 1st and March 31st of the measurement year, or report of previous receipt of an influenza immunization, or documentation of refusal. <i>(HRSAB HAB measure)</i>
90	Pneumococcal vaccine ever given or documentation of refusal. <i>(HRSAB HAB measure)</i>
91	Hepatitis B vaccine series completed or documentation of immunity, deferral, or refusal. <i>(HRSAB HAB measure)</i>
92	Hepatitis A vaccine series completed or documentation of immunity, deferral, or refusal.
93	Varicella-Zoster (VZV) , as medically indicated; Varicella titers at baseline, consider vaccination if negative titers and CD4 ₊ ≥200
94	Zoster vaccine (shingles vaccine) consideration if age >50 and CD4 ₊ ≥200
95	HPV administered to patients between ages 9 and 26 years or documentation of immunity, deferral, or refusal.
96	Meningococcal as medically indicated or documentation of refusal

Maintain
Archive
Maintain
Maintain
Maintain
Maintain
Archive
Maintain
Maintain
Archive

<i>IMMUNIZATIONS (Y = present; N = not present; N/A = not applicable)</i>	
53	Tetanus, Diphtheria, and Pertussis vaccine (Tdap): Percentage of patients with documented, Tdap or Td with booster every 10 years or documentation of refusal.
54	Influenza vaccine: Percentage of patients aged 6 months or older between October 1st and March 31st who received an influenza vaccination during the measurement year, or documentation of previous receipt of an influenza immunization, or documentation of refusal. <i>(HRSAB HAB measure)</i>
55	Pneumococcal vaccine: Percentage of patients with a diagnosis of HIV and a CD4 >200 cells/μL whom ever received a pneumococcal vaccine. <i>(HRSAB HAB measure)</i>
56	Hepatitis A vaccine: Percentage of patients with a diagnosis of HIV and documentation of the Hepatitis A vaccine series completed or documentation of immunity, deferral or refusal.
57	Hepatitis B vaccine: Percentage of patients with a diagnosis of HIV who completed the vaccine series for Hepatitis B or documentation of immunity, deferral, or refusal. <i>(HRSAB HAB measure)</i>
58	Zoster vaccine: Percentage of patients with a diagnosis of HIV and are age ≥50 with a CD4 ₊ ≥200 who ever received the Zoster vaccine.
59	Human Papilloma Virus vaccine (HPV): Percentage of patients with a diagnosis of HIV between ages 9 and 26 years who completed the series for HPV or with documentation of deferral or refusal.

ANTIBIOTIC TREATMENT (RECOMMEND PROPHYLACTIC ANTIBIOTIC TREATMENT)

97	MAC Prophylaxis: Percentage of patients who were prescribed antibiotic prophylaxis if CD4<50 (MAC) and/or if CD4<100 and toxoplasma IgG is positive.
----	---

Archive

ANTIRETROVIRAL THERAPY & RECOMMENDATIONS FOR PREVENTION AND TREATMENT OF PNEUMOCYSTIS PNEUMONIA (PCP) (Y = present; N = not present; NA = not applicable)				ANTIRETROVIRAL THERAPY & RECOMMENDATIONS FOR PREVENTION AND TREATMENT OF PNEUMOCYSTIS PNEUMONIA (PCP) (Y = present; N = not present; NA = not applicable)			
98		Percentage of patients, regardless of age, with a diagnosis of HIV are prescribed antiretroviral therapy for the treatment of HIV infection during the measurement year. <i>(HRS A HAB Measure)</i>	Maintain	60	ART	Prescription of HIV Antiretroviral Therapy: Percentage of patients, regardless of age, with a diagnosis of HIV are prescribed antiretroviral therapy for the treatment of HIV infection during the measurement year. <i>(HRS A HAB Measure)</i>	
99		Patients aged 6 weeks or older with CD4 counts of less than 200 cells/μL or a CD4 percentage below 15% prescribed PCP or documentation of deferral or refusal. <i>(HRS A HAB measure)</i>	Maintain	61		PCP Prophylaxis: Percentage of patients aged 6 weeks or older with CD4 counts of less than 200 cells/μL or a CD4 percentage below 15% prescribed PCP prophylaxis or documentation of deferral or refusal. <i>(HRS A HAB measure)</i>	
DRUG RESISTENCE TESTING (Y = present; N = not present; N/A = not applicable)							
100		Documented drug resistance testing was performed before initiation of HIV antiretroviral therapy if therapy started within the measurement year. <i>(HRS A HAB measure)</i>	Duplicate/Remove (new section)				
101		Documented drug resistance testing was performed if ARV naive, or experiencing ARV treatment failure.	Archive				
102		Drug Resistance Testing Counseling and Education must be provided by the patient's medical practitioner, registered nurse and/or other appropriate licensed healthcare provider (if designated by the practitioner).	Archive				
HEALTH EDUCATION/RISK REDUCTION (Y = present; N = not present; N/A = not applicable)				HEALTH EDUCATION/RISK REDUCTION (Y = present; N = not present; N/A = not applicable)			
103	Health Education/ Risk Reduction	HIV Risk Counseling: Percentage of patients with a diagnosis of HIV who received HIV risk counseling in the measurement year. <i>(HRS A HAB Measure)</i>	Maintain	62	Health Education/ Risk Reduction	HIV Risk Reduction Counseling: Percentage of patients with a diagnosis of HIV who received HIV risk counseling in the measurement year. <i>(HRS A HAB Measure)</i>	
104		Documented counseling within the past 12 months regarding increased risk of transmitting HIV during HIV infection and safer sexual practices.	Archive	63		STI Risk Reduction Counseling: Percentage of patients with documented counseling within the past 12 months about the risk of acquiring syphilis and other STIs from unprotected sexual contact, including all sites of possible transmission such as anus, cervix, vagina, urethra, and oropharynx.	
105		Documented counseling within the past 12 months about the risk of acquiring syphilis and other STIs from unprotected sexual contact, including all sites of possible transmission, such as anus, cervix, vagina, urethra, and oropharynx.	Maintain	64		Family Planning Counseling: Percentage of patients with documented counseling about family planning method appropriate to patient's status, as applicable to include preconception counseling.	
106		Documented counseling about family planning method appropriate to patient's status, as applicable.	Maintain	65		Tobacco Cessation Counseling: Percentage of patients aged 18 years and older who received cessation counseling intervention if identified as a tobacco user. <i>(HRS A HAB Measure)</i>	
107		Documented preconception counseling as appropriate.	Archive				
108		Documented instruction regarding new medications/ treatments/ tests as appropriate.	Archive				
109		Documented counseling regarding the importance of disclosure to partners.	Archive				
110			Tobacco Cessation: Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user. <i>(HRS A HAB Measure)</i>	Maintain (separate screening and cessation counseling)			
TREATMENT ADHERENCE (Y = present; N = not present; N/A = not applicable)				TREATMENT ADHERENCE (Y = present; N = not present; N/A = not applicable)			
111		Treatment Adherence Assessment Documented assessment for treatment adherence two or more times within the measurement year if patient on ARV	Maintain	66		Treatment Adherence Assessment: Documented assessment for treatment adherence two or more times within the measurement year if patient on ARV with a detectable viral load.	
112		Adherence Counseling If patient on ARVs with documented adherence issue, received counseled for treatment adherence two or more times within the measurement year.	Archive				
Referrals (Y = present; N = not present; N/A = not applicable)				Referrals (Y = present; N = not present; N/A = not applicable)			
113	Referrals	Referral for Health maintenance Documented referral as clinically appropriate: • Cervical Cancer Screening - annually after 2 negative screens 6 months apart • Family Planning - annually • Colorectal cancer screening - every 10 years unless patient condition indicated more frequent • Breast Cancer screening - annually unless patient condition indicated different frequency	Maintain (cervical cancer screening only)	67	Referrals	Cervical Cancer Screening: Percentage of patients with a referral each 3 years for Cervical Cancer screening after 2 negative screens 6 months apart if this service is not available on site at medical clinic.	
114		Referral for Adherence Counseling Documented referral made to medical case management for medication adherence if appropriate.	Archive	68		Referral for Oral Health: Percentage of patients with documented referral to dentist for Oral Healthcare in medical chart or that patient is already seeing dentist (can be patient self report).	
115		Referral for Mental Health/Substance Use Documented referral made to a mental health provider and/or substance use counselor if indicated.	Archive	69		Referral for Ophthalmology: Percentage of patients with documented referral to ophthalmologist if CD4 count is below 50.	
116		Referral for Oral Health Documented referral to dentist for Oral Health in medical chart or that patient is already seeing dentist (can be patient self report).	Maintain	70		Referral for Child Abuse: Percentage of patients with referral if suspected abuse is indicated; proper authorities contacted and documented in patient's file.	
117		Referral for Ophthalmic Documented referral if CD4 count was below 50.	Maintain				
118			Referral for Treatment Suitability Newly diagnosed HIV+/HCV patients have referral for treatment suitability and/or documented evaluation.	Archive			

119	Refer	Referral for Child Abuse If suspected abuse is indicated; proper authorities contacted and documented in patient's file.				
120		Referral to Disease Intervention Specialist Documented referral to case management or DIS if patient is not attending appointments.		Maintain		
121		Other Specialty Services Documented referral to specialty services as appropriate • AIDS Drug Assistance Program (ADAP) • Medication Assistance Programs • Medical care coordination • Medical specialties • Psychiatric and mental health services • Treatment education services • Substance use services • Partner counseling and referral • Medical Nutrition Therapy • HIV resources and support opportunities		Archive		
122		Follow-up on Referrals Each referral has a progress note in the patients chart regarding attendance and outcomes.		Archive		
DOCUMENTATION IN PATIENTS' MEDICAL CHART (Y = present; N = not present; N/A = not applicable)				DOCUMENTATION IN PATIENTS' MEDICAL CHART (Y = present; N = not present; N/A = not applicable)		
123		Signed clinician entries.		Maintain	71	Signed clinician entries: Percentage of patients with documented signed clinician entries on each medical visit during the measurement year.
124		Flow sheet present and updated.		Archive	72	Problem list present and updated: Percentage of patients with a documented problem list that is updated on each medical visit during the measurement year.
125		Problem list present and updated.		Maintain	73	Medication list present and updated: Percentage of patients with a documented medication list that is present and up to date on each medical visit during the measurement year.
126		Medication list present and updated.		Maintain		
DOCUMENTATION OF MISSED APPOINTMENTS AND EFFORTS TO BRING PATIENTS INTO CARE (Y = present; N = not present; N/A = not applicable)				DOCUMENTATION OF MISSED APPOINTMENTS AND EFFORTS TO BRING PATIENTS INTO CARE (Y = present; N = not present; N/A = not applicable)		
127		Documentation of a minimum of 3 different contacts (email, phone, mail, emergency contact, home visit by DIS) when patient has missed 3 scheduled appointments in 3-month period.		Archive	74	Missed Appointments: Percentage of patients with documentation of any specific barriers and efforts made to address missed appointments.
128		Documentation of any specific barriers and efforts made to address missed appointments.		Maintain		

* all indicators will be re-worded for consistency "percentage of patients with"

** indicators will be re-arranged so that the lab and screening sections of both the newly diagnosed and continuing in care sections mirror each other